Abstract: Processes are disclosed for the preparation of a compound having the formula: (I) and intermediate compounds wherein M is a single-photon-emission tomography imageable radiometal and/or a paramagnetic metal, R is hydrogen or a halogen provided that at least one R is halogen and Y is selected from ortho, meta or para O(CH2)nC2HB9H10 or O(CH2)nC2HB10H10 wherein n is 0 or an integer from 1 to 20 and O(CH2)nC2HB9H10 is nido ortho-, meta- or para-carborane and O(CH2)nC2HB10H10 is ortho-, meta- or para-carborane.

Abstract: The present invention relates to the use of a compound of formula (I) in the manufacture of a pharmaceuticals composition for cell death by photo activation therapy and the use of the compounds in the prevention and/or treatment of cancer.

Abstract: The present invention relates to new anti-cancer compounds and in particular to new compounds for use in nuclide activation therapy, such as neutron capture therapy. Specifically this invention provides a conjugate having the general formula P-(L-NAT)n wherein P represents an N-hydroxypropylmethacrylamide-methacrylate copolymer having a molecular weight of 5-6,000 kDa; NAT represents a nuclide activation therapy agent; L represents a linker moiety capable of linking the polymer to the neutron capture therapy agent; and n represents an integer from 1-1,000.

Abstract: Processes are disclosed for the preparation of a compound having the formula: (I) and intermediate compounds wherein M is a single-photon-emission tomography imageable radiometal and/or a paramagnetic metal, R is hydrogen or a halogen provided that at least one R is halogen and Y is selected from ortho, meta or para O(CH2)nC2HB9H10 or O(CH2)nC2HB10H10 wherein n is 0 or an integer from 1 to 20 and O(CH2)nC2HB9H10 is nido ortho-, meta- or para-carborane and O(CH2)nC2HB10H10 is ortho-, meta- or para-carborane.

Abstract: The present invention relates to new anti-cancer compounds and in particular to new compounds for use in nuclide activation therapy, such as neutron capture therapy. Specifically this invention provides a conjugate having the general formula P-(L-NAT)n wherein P represents an N-hydroxypropylmethacrylamide-methacrylate copolymer having a molecular weight of 5-6,000 kDa; NAT represents a nuclide activation therapy agent; L represents a linker moiety capable of linking the polymer to the neutron capturc therapy agent; and n represents an integer from 1-1,000.

Abstract: The present invention relates to immunoconjugates for use in neutron capture therapy, in particular Boron neutron capture therapy, for killing target cells such as tumours. The immunoconjugate of the invention comprises a monoclonal antibody having an affinity of at least 1011 l/mol and a cross-reactivity of less than 10%, and a neutron capture agent. More preferably, the affinity of the monoclonal antibody is at least 1012 l/mol.